chartexchange

Intellia Therapeutics Reports Q3 Loss of $127.5 Million and EPS of -$0.91, Missing Analyst Estimates

GuruFocus | Nov 6, 2026 2:00 AM EST

Pipeline Progress and Cash Runway Extend into 2028 Ahead of Key Regulatory Milestone Related Stocks: NTLA ,

Read original article